Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-3 trial
2024-516704-41-00Phase 4Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised trial of methotrexate, leflunomide, etanercept, tocilizumab, baricitinib and 12 more in rheumatoid arthritis (RA) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Low disease activity with low-dose corticosteroids at 11–12 months. Planned start Oct 2024; status: authorised.
02
Drugs
methotrexateleflunomideetanercepttocilizumabbaricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-516704-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516704-41-00.